WuXi AppTec / WuXi TIDES
WuXi STA's drug product services cover oral solids and injectables, integrating API and drug product development, analytical work, and clinical-to-commercial manufacturing.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
44 matching companies
WuXi STA's drug product services cover oral solids and injectables, integrating API and drug product development, analytical work, and clinical-to-commercial manufacturing.
Offers tablet, capsule, solution, and suspension development from early FIH/POC studies to market formulations, including spray drying, immediate-release, modified-release, and pediatric formulations.
Discloses ASD, spray-dried dispersion, hot-melt extrusion, and modified-release formulation development, supported by analytical data and early PK feedback for clinical manufacturing.
The group connects candidates with clinical and commercial supply through solid-state, preformulation, oral formulation development, and manufacturing services. Formulation execution entities include CFS and Candoo.
CFS is a wholly owned Crystal Pharmatech subsidiary offering development, analysis, and clinical-to-commercial manufacturing of conventional and ASD oral dosage forms, with disclosed spray drying and hot-melt extrusion capabilities.
Offers formulation services from preclinical work through FIH and commercial supply, with publicly listed preformulation and oral solid and injectable dosage form development.
This Canadian formulation provider uses QbD approaches for oral dosage form development and manufacturing process design, including immediate-release, controlled-release, bilayer, orally disintegrating, and sublingual products.
Offers early development of small-molecule oral and injectable products. Its biologics business provides formulation, stability, and compatibility development for vials, prefilled syringes, and cartridges.
Oral drug product services include preformulation, dosage form development, bioavailability enhancement, and clinical-to-commercial supply, with disclosed ASD and dissolution development services.
The Health Care business offers drug delivery and CDMO services for complex oral and injectable medicines, including functional polymers, solubility enhancement for poorly soluble drugs, and LNP formulation capabilities.
The solid-state and physicochemical team offers early enabling formulation prototypes to support preclinical performance. This record does not claim comprehensive commercial drug product manufacturing capability.
Offers formulation, analytical testing, GMP clinical batches, and stability studies for oral solids, sterile injectables, and complex products including nanomedicines.
Drug product services include preformulation, formulation and process development, and GMP manufacturing, supporting early clinical development, late-stage scale-up, and commercial supply.
Offers drug product R&D and manufacturing, with publicly listed oral solid, injectable, and biologic formulation development and scale-up services.
The Patheon service brand offers early development, late-stage scale-up, and commercial manufacturing of oral solid dosage forms, along with biologics analytical and formulation development.
Offers drug product formulation development and manufacturing for small molecules, TIDES, and bioconjugates. Its U.S. business discloses early oral formulation development and GMP supply.
Offers development and manufacturing of oral solids and specialized nonsterile dosage forms, with disclosed bioavailability enhancement for poorly soluble APIs, LNP formulation, and sterile injectable capabilities.
Offers oral solid dosage development linking formulation, process development, and risk assessment with the QTPP, for clinical and commercial supply.
Combines formulation development, clinical pharmacology, and manufacturing, including selection of solubility enhancement technologies, pediatric palatability improvement, and formulation development for multiple administration routes.
Connects spray-dried ASD and particle engineering with oral drug products, offering blending, dry granulation, tableting, coating, and encapsulation from formulation assessment through clinical batches.
Offers drug product CDMO services from formulation design and clinical materials through commercial manufacturing and packaging, including complex oral solids, injectables, and ophthalmic products.
A technology-focused CDMO specializing in small-molecule oral dosage forms, with disclosed formulation and analytical development for taste masking, tailored release, pediatric, and patient-friendly products.
Offers oral, nasal, pulmonary, and early-stage sterile formulation development, from feasibility and prototypes through scale-up and clinical manufacturing, addressing low solubility and stability challenges.
The unified Bend Bioscience brand brings together the former CoreRx, Societal, and Bend businesses, offering oral solids, oral liquids, ASD, and development from preformulation through process scale-up.
Coverage expands from sourced records; this database does not claim all biopharma companies.